Literature DB >> 26122838

Gene therapy for neurodegenerative diseases.

Deirdre M O'Connor1, Nicholas M Boulis2.   

Abstract

Gene therapy is, potentially, a powerful tool for treating neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS), spinal muscular atrophy, Parkinson's disease (PD) and Alzheimer's disease (AD). To date, clinical trials have failed to show any improvement in outcome beyond the placebo effect. Efforts to improve outcomes are focusing on three main areas: vector design and the identification of new vector serotypes, mode of delivery of gene therapies, and identification of new therapeutic targets. These advances are being tested both individually and together to improve efficacy. These improvements may finally make gene therapy successful for these disorders.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  clinical trial; gene therapy; neurodegenerative disease

Mesh:

Year:  2015        PMID: 26122838     DOI: 10.1016/j.molmed.2015.06.001

Source DB:  PubMed          Journal:  Trends Mol Med        ISSN: 1471-4914            Impact factor:   11.951


  26 in total

Review 1.  Viral vectors for therapy of neurologic diseases.

Authors:  Sourav R Choudhury; Eloise Hudry; Casey A Maguire; Miguel Sena-Esteves; Xandra O Breakefield; Paola Grandi
Journal:  Neuropharmacology       Date:  2016-02-21       Impact factor: 5.250

2.  Neuron-targeted caveolin-1 improves neuromuscular function and extends survival in SOD1G93A mice.

Authors:  Atsushi Sawada; Shanshan Wang; Minyu Jian; Joseph Leem; Jesse Wackerbarth; Junji Egawa; Jan M Schilling; Oleksandr Platoshyn; Alice Zemljic-Harpf; David M Roth; Hemal H Patel; Piyush M Patel; Martin Marsala; Brian P Head
Journal:  FASEB J       Date:  2019-03-20       Impact factor: 5.191

3.  Noninvasive delivery of an α-synuclein gene silencing vector with magnetic resonance-guided focused ultrasound.

Authors:  Kristiana Xhima; Fadl Nabbouh; Kullervo Hynynen; Isabelle Aubert; Anurag Tandon
Journal:  Mov Disord       Date:  2018-09-28       Impact factor: 10.338

Review 4.  The Potential Roles of Aquaporin 4 in Alzheimer's Disease.

Authors:  Yu-Long Lan; Jie Zhao; Tonghui Ma; Shao Li
Journal:  Mol Neurobiol       Date:  2015-10-03       Impact factor: 5.590

5.  Dual MicroRNA to Cellular Prion Protein Inhibits Propagation of Pathogenic Prion Protein in Cultured Cells.

Authors:  Sang-Gyun Kang; Chiye Kim; Judd Aiken; Han Sang Yoo; Debbie McKenzie
Journal:  Mol Neurobiol       Date:  2017-03-29       Impact factor: 5.590

Review 6.  Molecular Insights into NR4A2(Nurr1): an Emerging Target for Neuroprotective Therapy Against Neuroinflammation and Neuronal Cell Death.

Authors:  Md Jakaria; Md Ezazul Haque; Duk-Yeon Cho; Shofiul Azam; In-Su Kim; Dong-Kug Choi
Journal:  Mol Neurobiol       Date:  2019-01-25       Impact factor: 5.590

Review 7.  Neurotransmitter release: vacuolar ATPase V0 sector c-subunits in possible gene or cell therapies for Parkinson's, Alzheimer's, and psychiatric diseases.

Authors:  Haruhiro Higashida; Shigeru Yokoyama; Chiharu Tsuji; Shin-Ichi Muramatsu
Journal:  J Physiol Sci       Date:  2016-06-11       Impact factor: 2.781

Review 8.  Chemogenetics drives paradigm change in the investigation of behavioral circuits and neural mechanisms underlying drug action.

Authors:  Akihiko Ozawa; Hiroyuki Arakawa
Journal:  Behav Brain Res       Date:  2021-03-16       Impact factor: 3.332

9.  Restoration of Noradrenergic Function in Parkinson's Disease Model Mice.

Authors:  Kui Cui; Fan Yang; Turan Tufan; Muhammad U Raza; Yanqiang Zhan; Yan Fan; Fei Zeng; Russell W Brown; Jennifer B Price; Thomas C Jones; Gary W Miller; Meng-Yang Zhu
Journal:  ASN Neuro       Date:  2021 Jan-Dec       Impact factor: 4.146

10.  Efficient inhibition of ovarian cancer by degradable nanoparticle-delivered survivin T34A gene.

Authors:  Li Luo; Ting Du; Jiumeng Zhang; Wei Zhao; Hao Cheng; Yuping Yang; Yujiao Wu; Chunmei Wang; Ke Men; Maling Gou
Journal:  Int J Nanomedicine       Date:  2016-02-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.